Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response
Li, E., et al., Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response
- Categories
- Peer Reviewed Publications
Li, E., et al., Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response
Powles, T., et al., Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Johnson, K., et al., Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance
Johnson, J., et al., Genetic ancestry and racial differences in prostate tumours
Hu, M., et al., Circulating tumor cells in colorectal cancer in the era of precision medicine
Hsu, C., et al., 360 Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Kane L., et al., Multi-omic profiling of patient pancreatic cyst fluid for the identification of a novel biomarker panel of patient cancer risk
Yang, H., et al., Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma
Virdis, P., et al., Clarifying the molecular mechanism of tomentosin‑induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis
Santos, C., et al., 478P TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Yamoah, K., et al., Prostate tumors of native men from West Africa show biologically distinct pathways—A comparative genomic study
Lacerenza, S., et al., Biological processes associated with the efficacy of sunitinib plus nivolumab in soft tissue sarcoma: correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
Page last updated June 23, 2022